Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Liabilities (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Total Liabilities for 8 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 44.55% year-over-year to $57.2 million, compared with a TTM value of $57.2 million through Dec 2025, down 44.55%, and an annual FY2025 reading of $57.2 million, down 44.55% over the prior year.
  • Total Liabilities was $57.2 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $57.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $180.1 million in Q4 2022 and bottomed at $57.2 million in Q4 2025.
  • Average Total Liabilities over 5 years is $133.4 million, with a median of $144.3 million recorded in 2021.
  • The sharpest move saw Total Liabilities skyrocketed 188.08% in 2021, then crashed 46.88% in 2025.
  • Year by year, Total Liabilities stood at $164.6 million in 2021, then rose by 9.4% to $180.1 million in 2022, then decreased by 16.21% to $150.9 million in 2023, then crashed by 31.68% to $103.1 million in 2024, then plummeted by 44.55% to $57.2 million in 2025.
  • Business Quant data shows Total Liabilities for ARCT at $57.2 million in Q4 2025, $57.8 million in Q3 2025, and $78.2 million in Q2 2025.